|
Synonyms: IBI-306 | IBI306 | Sintbilo®
tafolecimab is an approved drug (China (2023))
Compound class:
Antibody
Comment: Tafolecimab (IBI-306; Innovent Biologics) is a fully human proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibody. Based on protein sequence alignments, we suspect that tafolecimab is one of the monoclonals that are claimed in Innovent Biologics' patent US11485795: Anti-PCSK9 antibody and use thereof [4].
|
| References |
|
1. Chai M, He Y, Zhao W, Han X, Zhao G, Ma X, Qiao P, Shi D, Liu Y, Han W et al.. (2023)
Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2). BMC Med, 21 (1): 77. [PMID:36855099] |
|
2. Cui Y, Zhao X, Qi L, Li X, Huang Z, Yang G, Qian L, Deng H, Li H, Huo Y. (2021)
A Potential Long-Acting LDL-Cholesterol-Lowering PCSK9 Monoclonal Antibody: Randomized, Placebo-Controlled Phase 1 Studies. JACC Asia, 1 (3): 411-415. [PMID:36341216] |
|
3. Keam SJ. (2023)
Tafolecimab: First Approval. Drugs, 83 (16): 1545-1549. [PMID:37847461] |
|
4. Tsun A, Krauland E, Belk JP, Maio X, Zhang M, Boland N, Liu X, Yo D. (2022)
Anti-PCSK9 antibody and use thereof. Patent number: US11485795B2. Assignee: Innovent Biologics Suzhou Co Ltd. Priority date: 03/04/2023. Publication date: 22/12/2017. |
